Søraas, Arne
Engvig, Andreas
Alnæs, Dag
Karim, Lana Nagmadin
Danilova, Elena
Istre, Mette Stausland
Nygaard, Sara
Utgård, Tone Reinton
Ceprnjic, Sandra
Reiakvam, Olaug
Edvardsen, Elisabeth
Westlye, Lars T.
Nygaard, Anders B.
Dahl, John Arne
Nissen-Meyer, Lise Sofie Haug
Ihle-Hansen, Håkon
Holland, Petter https://orcid.org/0000-0002-5717-6985
Funding for this research was provided by:
Longevity Impetus Grant from Norn Group
Nasjonalforeningen for Folkehelsen
University of Oslo
Article History
Received: 7 May 2026
Accepted: 15 July 2026
First Online: 23 July 2026
Declarations
Ethics approval and consent: The study was approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway, Subcommittee A application reference number 520697. This study was designed as a preliminary safety and feasibility assessment to inform the design of a subsequent randomized controlled trial. It was conducted in accordance with the Declaration of Helsinki. All data were processed according to EU/GDPR regulations. All patients provided written informed consent (Online Resource ) prior to enrollment, co-signed by their closest relative. All blood plasma donors provided written informed consent (Online Resource ) prior to blood plasma donation.
Conflict of interest: Arne Søraas is a founder and employee of the company Age Labs AS that develops molecular biomarkers for age-related diseases and aging. Andreas Engvig and Mette Stausland Istre are employees of Age Labs AS. John Arne Dahl acts as a scientific advisor to Age Labs AS. No resources or algorithms from Age Labs were used in this work. All other authors declare no conflicts of interest.
Trial registration: ClinicalTrials.gov NCT06234436 (registered 22 December 2023).